14 November 2019
As part of the program for the development of genetic technologies in Russia, three drugs will be created for the treatment of genetic diseases by 2027, Deputy Prime Minister Tatyana Golikova said in her report at a meeting held on November 12 in Novosibirsk, at State Research Center of Virology and Biotechnology VECTOR, where the role of world-class genomic research centers in the development of genetic technologies in Russia was discussed.
“The results that we are going to get under the program by 2027 – are at least 36 genetic technologies in medicine, agriculture and industry. This is about 20, and maybe even more, drugs, three of them will treat genetic diseases, at least five drugs for infectious diseases,”
Golikova said.
At the same time, Tatyana Golikova noted that Russia’s share in the market of genetic research and development is negligible, therefore it is extremely important to develop these competencies.
“In 2017, the market for genetic editing technologies was estimated at $3.2 billion, by 2022 it is assumed that this will be $6.3 billion, that is, this market is growing at a very fast pace – 14.5%, and we cannot work to lag behind,” - the Deputy Prime Minister of the Russian Federation emphasized.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Four cancer centers opened in Russia in 2023
26 April 2024
Russia and the UAE can simplify the drug registration process
26 April 2024
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024